The reimbursement challenges posed to both manufacturers developing digital medical technologies (DMTs) and the health authorities evaluating them are not to be underestimated. A new report spanning more than 200 pages from the Belgian Health Care Knowledge Centre (KCE) details the current evaluation and reimbursement landscape for DMTs in several European countries and outlines where limitations remain.
In particular, the ability for DMTs to be developed and updated more quickly than traditional medical devices and pharmaceutical products requires similarly speedy evaluation decisions, the report explains. Yet manufacturers...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?